A HER2 Specific Nanobody-Drug Conjugate: Site-Selective Bioconjugation and In Vitro Evaluation in Breast Cancer Models

Anders H Hansen; Kasper I H Andersen; Li Xin; Oliver Krigslund; Niels Behrendt; Lars H Engelholm; Claus H Bang-Bertelsen; Sanne Schoffelen; Katrine Qvortrup

doi:10.3390/molecules30020391

A HER2 Specific Nanobody-Drug Conjugate: Site-Selective Bioconjugation and In Vitro Evaluation in Breast Cancer Models

Anders H Hansen, Kasper I H Andersen, Li Xin, Oliver Krigslund, Niels Behrendt, Lars H Engelholm, Claus H Bang-Bertelsen, Sanne Schoffelen, Katrine Qvortrup^*

^*Corresponding author for this work

The Finsen Laboratory

4 Citations (Scopus)

Abstract

A human epidermal growth factor receptor 2 (HER2)-specific nanobody called 2Rs15d, containing a His3LysHis6 segment at the C-terminus, was recombinantly produced. Subsequent site-selective acylation on the C-terminally activated lysine residue allowed installation of the cytotoxin monomethyl auristatin E-functionalized cathepsin B-sensitive payload to provide a highly homogenous nanobody-drug conjugate (NBC), which demonstrated high potency and selectivity for HER2-positive breast cancer models.

Original language	English
Article number	391
Journal	Molecules
Volume	30
Issue number	2
ISSN	1420-3049
DOIs	https://doi.org/10.3390/molecules30020391
Publication status	Published - 18 Jan 2025

Keywords

breast cancer
nanobody
site-selective conjugation
targeted treatment

Access to Document

10.3390/molecules30020391Licence: CC BY

Cite this

@article{73e3973408974cf68aa61b96a6c88c6c,

title = "A HER2 Specific Nanobody-Drug Conjugate: Site-Selective Bioconjugation and In Vitro Evaluation in Breast Cancer Models",

abstract = "A human epidermal growth factor receptor 2 (HER2)-specific nanobody called 2Rs15d, containing a His3LysHis6 segment at the C-terminus, was recombinantly produced. Subsequent site-selective acylation on the C-terminally activated lysine residue allowed installation of the cytotoxin monomethyl auristatin E-functionalized cathepsin B-sensitive payload to provide a highly homogenous nanobody-drug conjugate (NBC), which demonstrated high potency and selectivity for HER2-positive breast cancer models.",

keywords = "breast cancer, nanobody, site-selective conjugation, targeted treatment",

author = "Hansen, \{Anders H\} and Andersen, \{Kasper I H\} and Li Xin and Oliver Krigslund and Niels Behrendt and Engelholm, \{Lars H\} and Bang-Bertelsen, \{Claus H\} and Sanne Schoffelen and Katrine Qvortrup",

year = "2025",

month = jan,

day = "18",

doi = "10.3390/molecules30020391",

language = "English",

volume = "30",

journal = "Molecules",

issn = "1420-3049",

publisher = "M D P I AG",

number = "2",

}

TY - JOUR

T1 - A HER2 Specific Nanobody-Drug Conjugate

T2 - Site-Selective Bioconjugation and In Vitro Evaluation in Breast Cancer Models

AU - Hansen, Anders H

AU - Andersen, Kasper I H

AU - Xin, Li

AU - Krigslund, Oliver

AU - Behrendt, Niels

AU - Engelholm, Lars H

AU - Bang-Bertelsen, Claus H

AU - Schoffelen, Sanne

AU - Qvortrup, Katrine

PY - 2025/1/18

Y1 - 2025/1/18

N2 - A human epidermal growth factor receptor 2 (HER2)-specific nanobody called 2Rs15d, containing a His3LysHis6 segment at the C-terminus, was recombinantly produced. Subsequent site-selective acylation on the C-terminally activated lysine residue allowed installation of the cytotoxin monomethyl auristatin E-functionalized cathepsin B-sensitive payload to provide a highly homogenous nanobody-drug conjugate (NBC), which demonstrated high potency and selectivity for HER2-positive breast cancer models.

AB - A human epidermal growth factor receptor 2 (HER2)-specific nanobody called 2Rs15d, containing a His3LysHis6 segment at the C-terminus, was recombinantly produced. Subsequent site-selective acylation on the C-terminally activated lysine residue allowed installation of the cytotoxin monomethyl auristatin E-functionalized cathepsin B-sensitive payload to provide a highly homogenous nanobody-drug conjugate (NBC), which demonstrated high potency and selectivity for HER2-positive breast cancer models.

KW - breast cancer

KW - nanobody

KW - site-selective conjugation

KW - targeted treatment

UR - https://www.scopus.com/pages/publications/85215767507

U2 - 10.3390/molecules30020391

DO - 10.3390/molecules30020391

M3 - Journal article

C2 - 39860260

SN - 1420-3049

VL - 30

JO - Molecules

JF - Molecules

IS - 2

M1 - 391

ER -

A HER2 Specific Nanobody-Drug Conjugate: Site-Selective Bioconjugation and In Vitro Evaluation in Breast Cancer Models

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this